Description

Compound Diisopropylamine Dichloroacetate (commonly known as DADA injection, brand Shibeixin) combines diisopropylamine dichloroacetate with sodium gluconate. DADA, a derivative of pangamic acid (“Vitamin B15”), is a hepatoprotective agent that enhances metabolic enzyme activity, supports liver detoxification, and improves bile flow. The injectable form is suitable for experimental and pharmacological studies on liver disorders, such as fatty liver, hepatic impairment, and early-stage cirrhosis.

Shibeixin is produced by Hunan Wuzhoutong Pharmaceutical Co., Ltd., following NMPA approval H20067194. Packaged as sterile liquid, 1?ml (20?mg) per vial × 10 vials.

Product Specifications

Mechanism of Action

DADA enhances liver metabolism by stimulating hepatic phospholipid methylation, increasing membrane fluidity, and activating Na?/K??ATPase. It supports mitochondrial respiration and promotes bile secretion, aiding in reducing fatty accumulation in hepatocytes.

Research Applications

• Fatty liver disease models

• Hepatic bile secretion and cholestasis studies

• Liver function recovery assays

• Hepatitis and early fibrosis/pre-cirrhosis experiments

• NADH/NAD metabolism and mitochondrial respiration research

Safety & Handling

• Use appropriate lab PPE (gloves, gown, eye protection)

• Intended for lab/experimental use only—no clinical administration

• Reported mild adverse effects in clinical contexts: dizziness, nausea, hypotension

• Store sealed, away from moisture and light

Core Keywords

DADA injection, compound diisopropylamine dichloroacetate, pangamic acid injection, Shibeixin injection, fatty liver research, liver metabolism injection, bile secretion enhancer, hepatoprotective injection

Research Use Disclaimer

This product is strictly for laboratory/research use. It is not approved for clinical, diagnostic, therapeutic, or veterinary applications. Misuse may pose legal or health risks—follow institutional protocols.